English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Cancer antigen 15–3 (CA 15–3), carcinoembryonic antigen  (CEA) and tissue polypeptide antigen (TPA) were measured in 679 sera of breast  cancer patients and in 94 sera of women without breast cancer. The tumour  markers were determined using immunoluminometric assays (ILMA). The assays are  characterised by an inter-assay-imprecision and intra-assay-imprecision &lt;4 %.  The breast cancer patients were staged according to the TNM classification stage  0–IV (by UICC) in patient groups with a compatible prognosis. Median and range  of each stage were investigated. The cut-off values (95th and 97.5th percentile  of control group) of CA 15–3, CEA and TPA were determined; specificity,  sensitivity, positive and negative predictive value (PV) and efficiency were  investigated for these cut-off's and the receiver operating characteristic (ROC)  curves were calculated. The differences between control group and stage 0–3 were  shown as non-significant for CA 15–3 and CEA but significant for TPA.  Significant differences were found in stage 4 for all three tumour markers. The  three tumour markers did not have differences in specificity, positive and  negative PV and efficiency. TPA and CA 15–3 demonstrated comparable results in  sensitivity and ROC curve analyses. These results were better than those from  CEA.

Comparison of Tissue Polypeptide Antigen (TPA) with Cancer Antigen 15-3 (CA 15-3) and Carcino-embryonic Antigen (CEA) in Follow-up of Breast Cancer